openPR Logo
Press release

Global Semaglutide Market Trends 2021 | Segmentation, Outlook, Industry Report to 2027

01-15-2022 07:35 AM CET | Health & Medicine

Press release from: Orion Market Research

The global semaglutide market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The major factor that is anticipated to drive the growth of the market includes the rise in the incidences of diabetes and obesity across the globe, which is expected to fuel the demand for Semaglutide during the forecast period, as it supports to control blood sugar levels and improves insulin sensitivity. Semaglutide is a glucagon-like peptide (GLP)-one agonist injected into the body. It works by increasing insulin production in response to elevated blood glucose levels while suppressing the excess secretion of glucagon from pancreas alpha cells which also reduces appetite and cravings for food.

The prolific rise in demand for novel therapies and innovative treatment options, owing to the increasing prevalence of TZDs has boosted the prospects of the Semaglutide market substantially. In addition, factors such as a strong product pipeline, favorable reimbursement policies throughout developed economies have also acted as a key driving factor that further adds momentum to the successful launch of these products across different geographies including North America and Europe regions. Moreover, growing awareness regarding therapeutic benefits offered by new generation GLP-I agonists has been an added advantage for manufacturers operating in this space.

To Request a Sample of our Report on Global Semaglutide Market: https://www.omrglobal.com/request-sample/semaglutide-market

In June 2021, Novo Nordisk A/S declared that the FDA has approved its diabetes medicine, semaglutide as a weekly 2.4 mg injection for weight management in people living with obesity. The GLP-1 product will be marketed by the brand name of Wegovy for chronic weight management in adults with obesity (initial BMI=30 kg/m2) or overweight (initial BMI=27 kg/m2) with at least one weight-related comorbidity, such as high blood pressure, type II diabetes, or high cholesterol.

The approval was based on data from the phase IIIa STEP study, which enrolled around 4,500 adults with overweight or obesity. Data from the study showed that people with obesity and without type II diabetes experienced an average weight loss of 17-18% sustained over 68 weeks. Semaglutide is presently approved by the trade name of Ozempic as a once-daily pre-filled pen to improve glycemic control in type II diabetes patients. It was also approved as an oral tablet by the brand name of Rybelsus in September 2019 in the United States and is now launched in 15 countries.

Market Coverage

· The market number available for – 2020-2027

· Base year- 2020

· Forecast period- 2021-2027

· Segment Covered

· Regions Covered- Globally

· Competitive Landscape: Novo Nordisk A/S

(Get 15% Discount on Buying this Report)

A full Report of Global Semaglutide Market is Available at: https://www.omrglobal.com/industry-reports/semaglutide-market

Global Semaglutide Market Report Segmentation

By Route of Administration

• Oral

• Injection

By Distribution Channel

• Hospital Pharmacies

• Retail Pharmacies

• Online Pharmacies

Global Semaglutide Market by Region

North America

· United States

· Canada

Europe

· UK

· Germany

· Spain

· France

· Italy

· Rest of Europe

Asia-Pacific

· India

· China

· Japan

· South Korea

· Rest of APAC

Rest of the World

Reasons to buy from us –

1. We cover more than 15 major industries, further segmented into more than 90 sectors.

2. More than 120 countries are for analysis.

3. Over 100+ paid data sources mined for investigation.

4. Our expert research analysts answer all your questions before and after purchasing your report.

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Semaglutide Market Trends 2021 | Segmentation, Outlook, Industry Report to 2027 here

News-ID: 2527856 • Views: 212

More Releases from Orion Market Research

Wireless Keyboard Market Overview by Recent Opportunities, Growth Size, Regional …
The global wireless Keyboard market is anticipated to grow at a considerable CAGR of 4.9% during the forecast period (2021-2027). Customers can connect wireless keyboards with many devices such as PC, smartphone & tablets, and with smart TVs. The wireless keyboards are high in demand due to its easy portability and compact design. The wireless keyboards canget connected through Wi-Fi, Bluetooth, and radio frequency, among others. The Bluetooth and Wi-Fi
Wheelchair Market Growth, Size, Share, Industry Report and Forecast 2021-2027
The global wheelchair market is anticipated to grow at a considerable CAGR of 6.2% during the forecast period (2021-2027). The rising prevalence of the disabled population is one of the prime factors affecting and driving the market. As per the data published by the World Health Organization (WHO) in December 2020, 1 billion people or 15% of the world’s population are suffering some form of disability. The disabled population is
Military Rotorcraft Market Top Leading Players with Strategies and Forecast 2027
The global military rotorcraft market is anticipated to grow significantly at a CAGR of 3.6% over the forecast period (2021-2027). The use of military rotorcraft has significantly increased in the past few years due to the increase in natural disasters. The aerial rescue mission has been identified as the most secure way of rescuing, which has increased the demand of aircraft among the nations for pre-preparing to resist casualties, transfer
Meat Alternatives Market 2021 Analysis May Set New Growth Story, Forecast to 202 …
The global meat alternatives market is anticipated to grow at a considerable CAGR of 7.5% during the forecast period (2021-2027). Meat production especially beef production has been found to be the biggest contributor for the occurrence of these greenhouse gases. Meat consumption is responsible for releasing greenhouse gases such as methane, CO2, and nitrous oxide. These gases contribute to climate change, such as global warming and others. Livestock use huge

All 5 Releases


More Releases for Semaglutide

The Relationship Between Vitamin D Deficiency And Type 1 Diabetes
Genetically determined vitamin D levels do not have a large effect on risk of type 1 diabetes in Europeans, according to a study published 25th February 2021 in the open-access journal PLOS Medicine by Despoina Manousaki from the CHU Sainte Justine and the University of Montreal, Canada and colleagues. Type 1 diabetes, once known as juvenile diabetes or insulin-dependent diabetes, is a chronic disease in which the pancreas produces little or no insulin. Type 1
Two New Diabetes Drugs Benefit For The Heart And Kidneys
Two new medications commonly used to treat type 2 diabetes are similar in their ability to reduce major heart complications, including heart attack, stroke and death from cardiovascular disease, according to research accepted for presentation at ENDO 2020, the Endocrine Society's annual meeting, and publication in a special supplemental section of the Journal of the Endocrine Society. One class of drugs, known as SGLT2 inhibitors, has a clear benefit over the
Biochempeg developed a series of PEG compounds used for Semaglutide
Type 2 diabetes is the most common form of diabetes. Semaglutide is an agonist of glucagon-like peptide-1 (GLP-1) receptor that is developed to treat type 2 diabetes. It reduces blood sugar via increasing the production of insulin. Biochempeg has developed and can supply some key intermediates of Semaglutide. Semaglutide(trade names: Rybelsus,Ozempic) is a medication for the treatment of type 2 diabetes. It was discovered in 2012, by a team of researchers
Semaglutide Market Size, Analytical Overview, Growth Factors, Demand, Trends and …
Complete study of the global Semaglutide market is carried out by the analysts in this report, taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape. This report offers a clear understanding of the present as well as future scenario of the global Semaglutide industry. Research techniques like PESTLE and Porter's Five Forces analysis have been deployed by the researchers. They have also provided accurate
Glucagon-Like Peptide-1 (Glp-1) Analogs Market Increasing the Growth Worldwide B …
Glucagon-like peptide-1 (GLP-1) analogs also known as incretin mimetics are class of drugs indicated for type-2 diabetes mellitus to lower the blood sugar level. GLP-1 analogs prevents the breakdown of GLP-1, thereby enhancing the glucose depended insulin release, suppresses the glucagon release (which reduces hepatic glucose output), and reduces gastric emptying rate (resulting in weight loss from reduced appetite). GLP-1 analogs do not cause hypoglycemia like other class of anti-diabetic
Binge Eating Disorder - Pipeline Review: Studied and Analyzed in a New Business …
Binge eating disorder is one of the main triggers of obesity and weight gain disorder across the globe. Denoted by uncontrolled eating behavior binge eating disorder has proved to cause major psychological downturn amongst sufferers. Triggered by a host of factors such as hereditary, psychological conditions, and emotional trauma amongst others, binge eating disorder continues to affect significant populace across regions. Market Research Hub (MRH) has collated a new business